Concurrent with the rise of digital health and personal health tracking technologies, a market has also emerged of products targeted specifically at women: ‘femtech’. This article is motivated by the concern that insufficient regulatory attention has been devoted to this growing market, and that extant ambiguity in the regulation of femtech leaves its users at risk of relying on technologies of as-yet unproven worth. It is posited that femtech profoundly disrupts well-established regulatory mechanisms of protection in ways that mean that these silos of protection will not be adequate. This is because regulation, as it is currently constructed, is insufficiently sensitive to feminist perspectives regarding what these technologies mean for women. As a result, the regulatory sphere in which femtech operates fundamentally fails to ensure that the health and safety of femtech users are protected as this market continues to expand. To counteract this, the argument is made that an appropriate regulatory response to femtech must respond to the distinctive unmet need in the regulation of this technological realm and the acute risk that femtech poses. This must include a multidimensional whole-system approach grounded in feminist perspectives on health, fertility, and technology.
CITATION STYLE
McMillan, C. (2022). MONITORING FEMALE FERTILITY THROUGH ‘FEMTECH’: THE NEED FOR A WHOLE-SYSTEM APPROACH TO REGULATION. Medical Law Review, 30(3), 410–433. https://doi.org/10.1093/medlaw/fwac006
Mendeley helps you to discover research relevant for your work.